Skip to main content

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Recruiting · Phase 1 · NCT06630806

Conditions: Plasma Cell Myeloma Refractory

At a glance

Research payments reported, 2025
$289,344
U.S. investigators named
5
Sites paid
5
Planned or actual enrollment
87

About the trial

Sponsor
Sanofi
Tested
SAR446523 (drug)
Dates
Started 2024-10-30; completion 2031-05-16
Results posted
Not yet

This is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 will be explored to determine the maximum administered dose (MAD), maximum tolerated dose (MTD), and recommended dose range (RDR) of 2 dose regimens which will be tested in the dose optimization part. Dose optimization (Part B): In this part, participants will be randomly assigned in a 1:1 ratio using interactive response technology (IRT) to either one of the chosen dose regimens of SAR446523 (determined from data coming from Part A), to determine the optimal dose as the recommended phase 2 dose (…

From ClinicalTrials.gov, last updated 2026-03-25. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Genzyme Corporation reported $289,344 in research payments for this study in 2025 (10 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.